3. A composition comprising a hydrate of the compound 15 (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl (1S,2R)-3-[[(4-aminophenyl)sulfonyl](isobutyl)amino]-1-benzyl-2-hydroxypropylcarbamate, in which the ratio of compound to water is about 1:0.5 to about 1:3, and an inert carrier.

4. The composition of claim 3 wherein the inert carrier is a pharmaceutically acceptable carrier.

5. The composition of claim 4 wherein the pharmaceutically acceptable carrier is a solid inert carrier.

**6.** A composition comprising a hydrate having the formula:

and an inert carrier.

32

7. The composition of claim 6 wherein the inert carrier is a pharmaceutically acceptable carrier.

**8**. The composition of claim **7** wherein the pharmaceutically acceptable carrier is a solid inert carrier.

**9**. The hydrate of claim **1** wherein the ratio of the compound to water is about 1:1 to about 1:2.

**10**. The hydrate of claim **1** wherein the ratio of the compound to water is about 1:0.5.

11. The hydrate of claim 1 wherein the ratio of the compound to water is about 1:1.

**12**. The hydrate of claim **1**, wherein the ratio of the compound to water is about 1:2.

13. The hydrate of claim 1 wherein the ratio of the compound to water is about 1:3.

**14**. The composition of claim **3** wherein the ratio of the compound to water is about 1:1 to about 1:2.

**15**. The composition of claim **3** wherein the ratio of the compound to water is about 1:0.5.

<sup>5</sup> **16**. The composition of claim **3** wherein the ratio of the compound to water is about 1:1.

17. The composition of claim 3 wherein the ratio of the compound to water is about 1:2.

<sup>30</sup> **18**. The composition of claim **3** wherein the ratio of the compound to water is about 1:3.

19. The composition of claim 3 further comprising amorphous (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl (1S, 2R)-3-[[(4-aminophenyl)sulfonyl](isobutyl)amino]-1-benzyl-2-hydroxypropylcarbamate.

\* \* \* \* \*